Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
72,987,327
-
Total 13F shares
-
23,119,889
-
Share change
-
+6,935,641
-
Total reported value
-
$361,544,722
-
Price per share
-
$15.68
-
Number of holders
-
54
-
Value change
-
+$108,357,037
-
Number of buys
-
43
-
Number of sells
-
10
Institutional Holders of Lexeo Therapeutics, Inc. - Common Stock (LXEO) as of Q1 2024
As of 31 Mar 2024 Lexeo Therapeutics, Inc. - Common Stock (LXEO) had 54 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 23,119,889 shares of stock of the company.
Largest 10 holders included EVENTIDE ASSET MANAGEMENT, LLC, JANUS HENDERSON GROUP PLC, D1 Capital Partners L.P., CITADEL ADVISORS LLC, Omega Fund Management, LLC, Novo Holdings A/S, ADAGE CAPITAL PARTNERS GP, L.L.C., BRAIDWELL LP, Artal Group S.A., and Blackstone Inc..
This table shows 54 institutional shareholders of the security as of 31 Mar 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.